Skip to main content

Table 3 Relationship between selected parameters and occurrence of posttransplant CMV infection

From: Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients

Characteristics

CMV infection

No CMV infection

p

N = 21

N = 65

Age, mean ± SD, y

51.4 ± 13.8

46.8 ± 15.6

0.244

Gender, male (%)

57.1

69.2

0.308

Type of transplant, Kidney /Kidney + pancreas (%)

24.4/25.0

75.6/75.0

0.977

Allograft function, (eGFR), mean ± SD

 Day 30

44.0 ± 15.4

50.2 ± 23.3

0.347

 Day 90

43.7 ± 17.4

52.6 ± 21.8

0.136

Blood transfusion, N Yes/No

12 /9

24 /38

0.140

Donor, D+/D- (%)

23.4/33.3

76.6/66.7

0.682

Pretransplant recipient CMV serostatus R+/R- (%)

22.4/33.1

77.6/66.9

0.410

The time of VGCV initiation after KTx (days); mean ± SD

9 ± 5

9 ± 5

0.905

The time of VGCV discontinuation after KTx (days); mean ± SD

94 ± 9

92 ± 14

0.458

Duration of antiviral prophylaxis (days); mean ± SD

85 ± 9

82 ± 15

0.382

total IgG concentration (g/L) < 7 / ≄7%

 Day 0

0.0/26.3

100.0/73.7

0.571

 Day 90

41.1/18.0

58.9/82.0

0.057

anti-CMV IgG titer (AU/ml) mean ± SD

 Day 0

138 ± 113

168 ± 109

0.803

 Day 90

113 ± 85

159 ± 109

0.087

leukocyte blood count (G/L) mean ± SD

 Day 0

7.8 ± 2.4

7.9 ± 2.3

1.000

 Day 30

8.5 ± 2.7

9.2 ± 4.0

0.800

 Day 90

6.6 ± 4.9

6.5 ± 3.2

0.080

Induction therapy (%)

  

0.026

 Yes basiliximab

25.8

74.2

 

 Yes thymoglobulin

57.1

42.9

 None

5.9

94.1

QuantiFERON-CMV assay (IU/mL) < 0.2/≄0.2 (%)

 All time points used

42.9/15.6

57.1/84.4

0.005

 Day 7

39.0/14.6

61.0/85.4

0.015

 Day 30

40.7/9.1

59.3/90.9

0.003

 Day 90

42.8/16.4

57.2/83.6

0.008

lymphocyte blood count (G/L) < 0.8/≄0.8 (%)

 Day 0

0.0/25.3

100.0/74.7

1.000

 Day 30

42.9/21.0

57.1/79.0

0.090

 Day 90

53.8/20.0

46.2/80.0

0.015

gammaglobulin blood concentration (g/dL) < 0.8/≄0.8 (%)

 Day 0

18.2/24.8

81.8/75.2

0.623

 Day 90

41.7/5.9

58.3/94.1

0.0004

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us